Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.63 |
| ▸ | TACR2 | P21452 | 2/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SHBG | P04278 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | TST | Q16762 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915276 | 1.00 | ESR1 (0.63) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL9753538 | 1.00 | ESR1 (0.63) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL7530233 | 1.00 | ESR1 (0.63) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL1611473 | 1.00 | ESR1 (0.63) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL698308 | 1.00 | ESR1 (0.63) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL1609476 | 0.98 | ESR1 (0.59) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL363054 | 0.91 | CA2 (0.54) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL23849704 | 0.88 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL2511615 | 0.88 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL10980557 | 0.88 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116987045-A | Heteroatom-containing substituted benzoxazinone derivative and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-11-03 | — | — | CN | claimed |
| US-20220213210-A1 | COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND | MABION SA (PL) | 2022-07-07 | — | — | US | claimed |
| EP-3720880-A1 | COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND | Mabion SA (PL) | 2020-10-14 | — | — | EP | claimed |
| WO-2019110643-A1 | COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND | MABION SA (PL) | 2019-06-13 | — | — | WO | claimed |
| US-20170312249-A1 | MODULATORS OF 14-3-3 FUNCTIONALITY AND USES THEREOF | UNIVERSITY OF SOUTH AUSTRALIA (AU) | 2017-11-02 | — | — | US | claimed |
| WO-2016054680-A1 | MODULATORS OF 14-3-3 FUNCTIONALITY AND USES THEREOF | UNIVERSITY OF SOUTH AUSTRALIA (AU) | 2016-04-14 | — | — | WO | claimed |
| CN-103724215-A | Novel derivative of 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propandiol and application of novel derivative | ZHENJIANG SHENGAN PHARMACEUTICAL CO LTD | 2014-04-16 | — | — | CN | claimed |
| CN-101478961-B | S1P receptor modulators for the treatment of multiple sclerosis | NOVARTIS AG | 2013-11-27 | — | — | CN | claimed |
| CN-101797241-B | Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol | NOVARTIS AG | 2013-03-27 | — | — | CN | claimed |
| CN-101068536-B | Dosage regimen of an S1P receptor agonist | NOVARTIS AG | 2012-12-05 | — | — | CN | claimed |
| CN-1993115-B | Compound formulations of 2-amino-1, 3-propanediol compounds | NOVARTIS AG (CH) | 2011-12-28 | — | — | CN | claimed |
| CN-1893934-B | Use of sphingosine-1-phosphate (S1P) receptor agonists for the manufacture of a medicament for the treatment of brain degenerative diseases | NOVARTIS AG | 2010-05-26 | — | — | CN | claimed |
| CN-101478961-A | S1P receptor modulators for the treatment of multiple sclerosis | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | claimed |
| US-20070270499-A1 | Use for 2-amino-2-propane-1, 3-diols | WELSCH CAROLE | 2007-11-22 | — | — | US | claimed |
| US-20040214897-A1 | Uses for 2-amino-2-propane-1,3-diols | WELSCH CAROLE | 2004-10-28 | — | — | US | claimed |
| WO-2003009836-A2 | NEW USES FOR 2-AMINO-2-PROPANE-1,3-DIOLS | NOVARTIS AG (CH) | 2003-02-06 | — | — | WO | claimed |
| WO-1999014204-A1 | SUBSTITUTED 1,2,4-TRIAZOLES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | G.D. SEARLE & CO. (US) | 1999-03-25 | — | — | WO | claimed |
| CN-116987045-A | Heteroatom-containing substituted benzoxazinone derivative and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-11-03 | — | — | CN | disclosed |
| US-3957854-A | FUEL ADDITIVES, LUBRICANTS | THE LUBRIZOL CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
| US-3957855-A | FUEL ADDITIVES, LUBRICANTS | THE LUBRIZOL CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214897-A1 | Uses for 2-amino-2-propane-1,3-diols | DGKB, GLS2, GLS | ESR1 2376/4885ADRA2A 720/4885ADORA3 3010/4885 |
| US-20070270499-A1 | Use for 2-amino-2-propane-1, 3-diols | DGKB, GLS2, GLS | ESR1 1805/4885ADRA2A 556/4885ADORA3 2308/4885 |
| US-20170312249-A1 | MODULATORS OF 14-3-3 FUNCTIONALITY AND USES THEREOF | YWHAH, YWHAG, YWHAB | ESR1 4271/4885ADRA2A 4651/4885ADORA3 4060/4885 |
| US-20220213210-A1 | COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND | CD209, MSR1, SIGLEC7 | ESR1 2741/4885ADRA2A 1382/4885ADORA3 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.